Zobrazeno 1 - 4
of 4
pro vyhledávání: '"J López-Santamaria Donoso"'
Autor:
IReyes Torres, J Hernandez Parada, TLopez Viñau Lopez, López Malo de Molina, J López-Santamaria Donoso, M Sáez-Torres de Vicente
Publikováno v:
Eur J Hosp Pharm
Background Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is currently among the most commonly used antiretroviral agents. Recent reports have raised concerns about their safety, especially with regard to neurops
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3830be9916fa7c9e8afaf93f4c07038f
https://europepmc.org/articles/PMC7535272/
https://europepmc.org/articles/PMC7535272/
Autor:
J López-Santamaria Donoso, I Reyes-Torres, P Montejano-Hervás, Aumente, MA Rodríguez Villa, Javier Molina
Publikováno v:
Pharmacokinetics and pharmacodynamics.
Background The use of intrathecal (IT) methotrexate (MTX) in combination with systemic high dose MTX (HDMTX) is an established procedure for CNS prophylaxis in patients with acute lymphoblastic leukaemia (ALL), but the evidence for the necessity of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70d2c0f40919a0066ee804eda08960e9
https://doi.org/10.1136/ejhpharm-2017-000640.440
https://doi.org/10.1136/ejhpharm-2017-000640.440
Publikováno v:
Pharmacokinetics and pharmacodynamics.
Background The strong degree of structural similarity between everolimus and sirolimus (SRL) causes cross reactivity between them. The underestimation observed with the everolimus quantitative microsphere system (QMS) led many centres to opt for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfd4b61755f4b76d6c7c03e14bf88f5f
https://doi.org/10.1136/ejhpharm-2017-000640.446
https://doi.org/10.1136/ejhpharm-2017-000640.446
Autor:
P Montejano-Hervás, MC Donoso Rengifo, A Gago-Sanchez, J López-Santamaria Donoso, I Reyes-Torres
Publikováno v:
European Journal of Hospital Pharmacy. 23:A98.3-A99
Background Eribulin is approved for use in pretreated metastatic breast cancer (MBC) patients after at least two chemotherapy regimens for advanced disease. Purpose To assess the effectiveness and safety of eribulin in MBC. Material and methods Retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1904db324399ac9ac27827de6ecf7de7
https://doi.org/10.1136/ejhpharm-2016-000875.223
https://doi.org/10.1136/ejhpharm-2016-000875.223